CTXR
Citius Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Citius Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Linked news
Citius Pharmaceuticals has 5 disclosed suppliers and 3 disclosed customers in SEC filings.
SentenceIn September 2021, the
Company entered into an asset purchase agreement with Dr. Reddy's and a license agreement with Eisai to acquire an exclusive license
of E7777 (denileukin diftitox), an oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma.
SentenceIn September 2021, the
Company entered into an asset purchase agreement with Dr. Reddy's and a license agreement with Eisai to acquire an exclusive license
of E7777 (denileukin diftitox), an oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma.
CTXR 10-Kaccession 0001213900-25-125333
SentenceCitius Oncology has contracted with EVERSANA an innovative AI platform, to support the launch and commercialization of LYMPHIR whereby
CTXR 10-Kaccession 0001213900-25-125333
SentenceMino-Lok® – LMB has a patent
and technology license agreement with Novel Anti-Infective Therapeutics, Inc. ("NAT") to develop and commercialize Mino-Lok
on an exclusive, worldwide sub-licensable basis, as amended.
CTXR 10-Kaccession 0001213900-25-125333
SentenceOn October 6, 2020, our
subsidiary NoveCite entered into a license agreement with Novellus Therapeutics Limited, whereby NoveCite acquired an exclusive, worldwide
CTXR 10-Kaccession 0001213900-25-125333
Citius Pharmaceuticals, Inc.
0.53
Expected move
No implied move.